Literature DB >> 1884541

Endoprosthetic replacement for stage IIB osteosarcoma.

J J Eckardt1, F R Eilber, G Rosen, J M Mirra, F J Dorey, W G Ward, J M Kabo.   

Abstract

Over an eight-year period, 100 patients with IIB osteosarcoma have been managed. Eighty-one were treated with limb-salvage procedures, 78 of which involved reconstruction utilizing endoprostheses. Only 19 patients received amputation as the primary treatment for local control. Since 1984, all patients received preoperative and post-operative adjuvant chemotherapy. Those patients who received chemotherapy had a statistically significant improvement in five-year survival over those who did not (57% and 32%, respectively, p = 0.014). The functional results were good overall, with excellent results seen in distal femoral reconstruction. Twenty-eight of the 78 patients treated with endoprosthetic reconstruction experienced 30 complications (36%). Mechanical failure was the most common complication (10%) but was generally correctable. The local recurrence rate was 5% and the infection rate was 3%. Local complications were manageable. A statistical analysis revealed that the relative risk of patient death was 2.5 times higher than prosthesis failure for the 78 patients with endoprosthetic reconstruction. The intermediate-term results, with a median follow-up period of 43 months, remains encouraging.

Entities:  

Mesh:

Year:  1991        PMID: 1884541

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  18 in total

Review 1.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

2.  Early distal femoral endoprosthetic survival: cemented stems versus the Compress implant.

Authors:  A A Bhangu; M J Kramer; R J Grimer; R J O'Donnell
Journal:  Int Orthop       Date:  2006-09-16       Impact factor: 3.075

3.  Long-term outcomes of cement in cement technique for revision endoprosthesis surgery.

Authors:  Nicholas M Bernthal; Vishal Hegde; Stephen D Zoller; Howard Y Park; Jason H Ghodasra; Daniel Johansen; Frederick Eilber; Fritz C Eilber; Chandhanarat Chandhanayingyong; Jeffrey J Eckardt
Journal:  J Surg Oncol       Date:  2017-10-29       Impact factor: 3.454

4.  The current state of limb salvage surgery.

Authors:  Henry J Mankin
Journal:  Skeletal Radiol       Date:  2009-08       Impact factor: 2.199

5.  Perioperative infection rate in patients with osteosarcomas treated with resection and prosthetic reconstruction.

Authors:  Xin Li; Vincent M Moretti; Adedayo O Ashana; Richard D Lackman
Journal:  Clin Orthop Relat Res       Date:  2011-05-12       Impact factor: 4.176

Review 6.  Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature.

Authors:  S R Babin; P Simon; A Babin-Boilletot; J P Bellocq
Journal:  Int Orthop       Date:  1995       Impact factor: 3.075

7.  Megaprosthesis versus Condyle-sparing intercalary allograft: distal femoral sarcoma.

Authors:  Melissa N Zimel; Amy M Cizik; Timothy B Rapp; Jason S Weisstein; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2009-08-07       Impact factor: 4.176

8.  Treatment solutions are unclear for perimegaprosthetic infections.

Authors:  Lisa B Ercolano; Tyson Christensen; Richard McGough; Kurt Weiss
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

9.  Total knee replacement versus osteochondral allograft in proximal tibia bone tumours.

Authors:  M Colangeli; D Donati; M G Benedetti; F Catani; E Gozzi; E Montanari; S Giannini
Journal:  Int Orthop       Date:  2007-03-29       Impact factor: 3.075

10.  Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants.

Authors:  Adam J Schwartz; J Michael Kabo; Fritz C Eilber; Frederick R Eilber; Jeffrey J Eckardt
Journal:  Clin Orthop Relat Res       Date:  2009-12-22       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.